Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07158229

Long-term Impact of NMDAR Encephalitis, Level 3

Social and Psychological Long-term Impact of NMDA Receptor Encephalitis, Level 3

Status
Recruiting
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnairesComplete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep.

Timeline

Start date
2025-11-21
Primary completion
2026-11-21
Completion
2026-11-21
First posted
2025-09-05
Last updated
2026-02-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07158229. Inclusion in this directory is not an endorsement.